After finishing at $71.47 in the prior trading day, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $71.96, up 0.69%. In other words, the price has increased by $+0.49 from its previous closing price. On the day, 1293188 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of CRSP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.54 and its Current Ratio is at 17.54. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On December 11, 2023, TD Cowen Downgraded its rating to Underperform which previously was Market Perform but kept the price unchanged to $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Kulkarni Samarth sold 20,000 shares for $72.48 per share. The transaction valued at 1,449,628 led to the insider holds 208,122 shares of the business.
Prasad Raju sold 3,524 shares of CRSP for $256,160 on Mar 15 ’24. The Chief Financial Officer now owns 6,476 shares after completing the transaction at $72.69 per share. On Mar 12 ’24, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 4,583 shares for $74.44 each. As a result, the insider received 341,159 and left with 208,122 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5.74B and an Enterprise Value of 4.28B. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.32 while its Price-to-Book (P/B) ratio in mrq is 3.06. Its current Enterprise Value per Revenue stands at 11.57 whereas that against EBITDA is -21.12.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $37.55. The 50-Day Moving Average of the stock is 72.32, while the 200-Day Moving Average is calculated to be 58.86.
Shares Statistics:
The stock has traded on average 2.14M shares per day over the past 3-months and 1.41M shares per day over the last 10 days, according to various share statistics. A total of 80.04M shares are outstanding, with a floating share count of 79.98M. Insiders hold about 5.01% of the company’s shares, while institutions hold 64.47% stake in the company. Shares short for CRSP as of Feb 29, 2024 were 15.06M with a Short Ratio of 7.05, compared to 15.74M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 18.76% and a Short% of Float of 19.01%.
Earnings Estimates
Its stock is currently analyzed by 17 different market analysts. On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of $0.74 and a low estimate of -$1.82, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$1.53, with high estimates of -$1.02 and low estimates of -$1.81.
Analysts are recommending an EPS of between -$2.6 and -$7.48 for the fiscal current year, implying an average EPS of -$5.71. EPS for the following year is -$4.32, with 20 analysts recommending between $5.08 and -$7.95.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $427.9M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $105.82M. In the same quarter a year ago, actual revenue was $371.21M, down -71.50% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $405.2M in the next fiscal year. The high estimate is $3.31B and the low estimate is $40M. The average revenue growth estimate for next year is up 282.90% from the average revenue estimate for this year.
